{
    "organizations": [],
    "uuid": "e1b344b5aa6e629ebf50d5406a45cb9b850287a5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-inovio-awarded-up-to-56-million-fr/brief-inovio-awarded-up-to-56-million-from-cepito-advance-dna-vaccines-against-lassa-fever-and-mers-idUSFWN1RO0PG",
    "ord_in_thread": 0,
    "title": "BRIEF-Inovio Awarded Up To $56 Million From Cepi To Advance Dna Vaccines Against Lassa Fever And Mers",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 11 (Reuters) - Inovio Pharmaceuticals Inc:\n* INOVIO AWARDED UP TO $56 MILLION FROM CEPI TO ADVANCE DNA VACCINES AGAINST LASSA FEVER AND MERS\n* ANNOUNCED PARTNERSHIP UNDER WHICH CO WILL DEVELOP VACCINE CANDIDATES AGAINST LASSA FEVER AND MIDDLE EAST RESPIRATORY SYNDROME\n* 4700 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-11T20:09:00.000+03:00",
    "crawled": "2018-04-12T13:48:11.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "inovio",
        "pharmaceutical",
        "inc",
        "inovio",
        "awarded",
        "million",
        "cepi",
        "advance",
        "dna",
        "vaccine",
        "lassa",
        "fever",
        "mers",
        "announced",
        "partnership",
        "co",
        "develop",
        "vaccine",
        "candidate",
        "lassa",
        "fever",
        "middle",
        "east",
        "respiratory",
        "syndrome",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}